Naturally Splendid (CVE: NSP- OTCPINK: NSPDF) CEO Craig Goodwin joined Steve Darling from Proactive to share news the company has responded to Health Canada's Information Request Notice. The IRN was designed to determine the final dosage of Cavaltinib intended for use as a COVID treatment and to define the final criteria for the selection of patients making up the test and control groups for the trial.
Goodwin talks about this step in the process and of they have been given any timelines from Health Canada.
